{"organizations": [], "uuid": "5b6113f4080cd0db93423c777c1f51ef6540cd49", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180515.html", "section_title": "Archive News &amp; Video for Tuesday, 15 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-atossa-genetics-receives-positive/brief-atossa-genetics-receives-positive-interim-safety-review-in-phase-1-topical-endoxifen-dose-escalation-study-idUSFWN1SM108", "country": "US", "domain_rank": 408, "title": "BRIEF-Atossa Genetics Receives Positive Interim Safety Review In Phase 1 Topical Endoxifen Dose Escalation Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.125, "site_type": "news", "published": "2018-05-15T20:14:00.000+03:00", "replies_count": 0, "uuid": "5b6113f4080cd0db93423c777c1f51ef6540cd49"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-atossa-genetics-receives-positive/brief-atossa-genetics-receives-positive-interim-safety-review-in-phase-1-topical-endoxifen-dose-escalation-study-idUSFWN1SM108", "ord_in_thread": 0, "title": "BRIEF-Atossa Genetics Receives Positive Interim Safety Review In Phase 1 Topical Endoxifen Dose Escalation Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-atossa genetics receives positive interim safety review", "sentiment": "negative"}, {"name": "atossa genetics inc", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 15 (Reuters) - Atossa Genetics Inc:\n* ATOSSA GENETICS RECEIVES POSITIVE INTERIM SAFETY REVIEW FROM INDEPENDENT SAFETY COMMITTEE IN PHASE 1 TOPICAL ENDOXIFEN DOSE ESCALATION STUDY IN MEN\n* ATOSSA GENETICS INC - INDEPENDENT SAFETY COMMITTEE REVIEWED BLINDED DATA CONCLUDED STUDY MAY ADVANCE TO FINAL DOSING LEVEL Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-15T20:14:00.000+03:00", "crawled": "2018-05-16T18:45:47.003+03:00", "highlightTitle": ""}